Phenominer Database Results (324 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Average Type Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Stieber D, et al., Int J Cancer. 2007 Jan 17 mammary gland integrity trait female 186 days-191 days 14 3.93 null 0.17 0.64 necropsy 0 DMBA oral gavage 0 necropsy 11341 73
COP/CrCrl mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 7 0.1 null 0.15 0.4 necropsy 0 11370 75
DA/Slc number of squamous cell tumors of the tongue with diameter greater than 3 mm controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 1.6 null 0.17 0.75 necropsy 0.0 0 180 day maximum 70320 1339
SS.SHR-(D9Mco72-D9Mco105)/Mco age at time of death controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 104 and 106 days) Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. total life span not specified 0 days 8 median 146.0 d necropsy 0.0 0 visual observation 69610 749
WF.COP-(D2Mit29-D2Rat201)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 mammary gland integrity trait female 155 days-160 days 19 1.5 null 0.3 1.31 necropsy 0.0 0 3X3 mm diameter or larger 70168 143
BDIX/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 52 Kaplan-Meier estimate 41.5 % 1.07 7.75 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98098 1998
BDIX.BDIV-D10Mit3-D10Mgh16/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 37 Kaplan-Meier estimate 2.9 % 0.33 2.0 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98100 1998
BDIX.BDIV-D10Got1-D10Rat45/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 40 Kaplan-Meier estimate 17.2 % 0.99 6.25 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98102 1998
BDIX post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 181 days-213 days 57 Kaplan Meier estimate median 197.0 d 1.06 8.0 necropsy 0.0 0 SD approximated from 95%CI 98125 2018
BDIX post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 190 days-213 days 109 Kaplan Meier estimate median 201.0 d 0.55 5.75 necropsy 0.0 0 SD approximated from 95%CI 98127 2018
BDIX.BDIV-D6Rat132-D6Rat229/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 0 days 24 Kaplan Meier estimate median 227.0 d necropsy 0.0 0 98135 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 215 days-257 days 62 Kaplan Meier estimate median 236.0 d 1.33 10.5 necropsy 0.0 0 SD approximated from 95%CI 98137 2018
BDIV post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 0 days 63 Kaplan Meier estimate median 593.0 d necropsy 0.0 0 98139 2018
BDIV post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 0 days 49 Kaplan Meier estimate median 482.0 d necropsy 0.0 0 98140 2018
BDIX.BDIV-D10Mit3-D10Mgh16/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 75 Kaplan-Meier estimate 7.9 % 0.52 4.5 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98178 1998
BDIX.BDIV-D10Got1-D10Rat45/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 77 Kaplan-Meier estimate 22.5 % 0.48 4.25 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98179 1998
SS.ZUC-Leprfa+/+/Slc ratio of survivors of metabolic syndrome to total study population during a period of time control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total life span male 126 days 6 100.0 % necropsy 0.0 0 ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) 101909 2642
BDIX/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 32 20.5 % necropsy 0.0 12 days 111321 3199
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % 0.0 0.0 necropsy 0.0 0 saline control group 111124 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-164 days 18 22.0 % necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111156 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-186 days 21 9.5 % necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111157 3196
SD-Cftrem2Apb percentage of study population developing meconium ileus during a period of time controlled ColonLYTELY content drinking water (4.5 %) (for 7 days) McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. intestine integrity trait not specified 7 days 0 40.0 % 0.0 necropsy 0.0 0 percentage of study population developing meconium ileus during a period of time (CMO:0003881) 111464 3184
WM/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 28 25.7 % necropsy 0.0 12 days 111289 3199
WM/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 21 14.8 % necropsy 0.0 12 days 111297 3199
BDIX/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 60 0.0 % necropsy 0.0 12 days 111306 3199
BDIX/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 32 13.3 % necropsy 0.0 12 days 111307 3199
WM/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 43 0.0 % necropsy 0.0 12 days 111308 3199
WM/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 28 5.9 % necropsy 0.0 12 days 111310 3199
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 50 53.2 % necropsy 0.0 12 days 111238 3199
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 11 58.6 % necropsy 0.0 12 days 111272 3199
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 10 51.6 % necropsy 0.0 12 days 111274 3199
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait female 0 days 49 9.6 % necropsy 0.0 200 days 111211 3198
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 74 45.5 % necropsy 0.0 12 days 111237 3199
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 141 0.0 % necropsy 0.0 12 days 111242 3199
WM/Nem number of blastocysts implanted per litter trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 11 10.5 null necropsy 0.0 12 days 111263 3199
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 12 51.5 % necropsy 0.0 12 days 111273 3199
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 141 1.7 % necropsy 0.0 12 days 111233 3199
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 85 3.7 % necropsy 0.0 12 days 111253 3199
BDIX/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 73 0.0 % necropsy 0.0 12 days 111259 3199
LOU/MWsl post-treatment survival time from doxorubicin-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then 0.9% sodium chloride solution van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. life span trait male 110 days-116 days 9 median 8.0 d 0.0 0.0 necropsy 0.0 0 post-treatment survival time from doxorubicin-treated IgM immunocytoma (CMO:0003866) 109572 3150
WM/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111322 3199
WM/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 30 16.0 % necropsy 0.0 12 days 111323 3199
WM/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 46 12.1 % necropsy 0.0 12 days 111324 3199
WM/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111329 3199
WM/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 30 7.6 % necropsy 0.0 12 days 111330 3199
WM/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 46 9.4 % necropsy 0.0 12 days 111331 3199
BDIX/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 0.0 % necropsy 0.0 12 days 111334 3199
BDIX/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 31 3.3 % necropsy 0.0 12 days 111335 3199
WM/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 30 8.3 % necropsy 0.0 12 days 111337 3199
WM/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 96 0.0 % necropsy 0.0 12 days 111343 3199
WM/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 46 8.3 % necropsy 0.0 12 days 111345 3199
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-147 days 14 median 84.0 d 3.61 13.5 necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111122 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111131 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 111134 3196
WM/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 29 0.0 % necropsy 0.0 12 days 111367 3199
WM/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 96 28.7 % necropsy 0.0 12 days 111371 3199
WM/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 30 57.8 % necropsy 0.0 12 days 111372 3199
WM/Nem number of blastocysts implanted per litter trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 10 12.9 null necropsy 0.0 12 days 111265 3199
BDIX/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 16 34.8 % necropsy 0.0 12 days 111276 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 85 5.2 % necropsy 0.0 12 days 111280 3199
BDIX/Ifz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait male 0 days 17 72.9 % necropsy 0.0 200 days 111207 3198
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait male 0 days 51 38.2 % necropsy 0.0 200 days 111210 3198
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 80.0 % 0.0 0.0 necropsy 0.0 30 days group C 111030 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 2 111032 3195
SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 14 4.86 null 0.7 2.63 necropsy 0 DMBA oral gavage 105 days necropsy 65573 86
ACI.COP-(D10Mgh8-D10Rat4)/Shul mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 3 0.0 null necropsy 0 11365 75
BN/SsNHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait female 0 days 36 0.0 % necropsy 0.0 0 69373 1157
WF/NHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 mammary gland integrity trait female 155 days-160 days 29 6.3 null 0.5 2.69 necropsy 0.0 0 3X3 mm diameter or larger 70167 143
WF/Kga squamous cell carcinoma of the tongue tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 1.0 null 0.15 0.65 necropsy 0.0 0 180 day maximum 70315 1339
SPRD/Ztm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Stieber D, et al., Int J Cancer. 2007 Jan 17 mammary gland integrity trait female 186 days-191 days 48 11.23 null 0.07 0.51 necropsy 0 DMBA oral gavage 0 necropsy 11340 73
COP/CrCrl mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 5 0.0 null necropsy 0 11369 75
WF/NHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 mammary gland integrity trait female 155 days-160 days 30 8.1 null 0.7 3.83 necropsy 0 3X3 mm diameter or larger 11746 143
WF.DA-(D19Mit1-D19Mit6)/Kop squamous cell carcinoma of the tongue tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 23 1.65 null 0.15 0.71 necropsy 0.0 0 180 day maximum 70316 1339
SS/Jr age at time of death controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 66 and 68 days) Kumarasamy S, et al., Hypertens Res. 2011 Dec;34(12):1263-70. doi: 10.1038/hr.2011.116. Epub 2011 Aug 4. total life span not specified 0 days 8 median 108.0 d necropsy 0.0 0 visual observation 69608 749
WF squamous cell carcinoma of the tongue tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 50 0.42 null 0.07 0.5 necropsy 0.0 0 until moribund or 180days of exp error type not specified 70396 1398
WF squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 head and neck integrity trait both 42 days-222 days 50 1.26 null 0.21 1.45 necropsy 0.0 0 until moribund or 180days of exp error not specified 70402 1398
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 20 0.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68125 838
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 23 61.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68129 838
BDIX/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait male 0 days 57 Kaplan-Meier estimate median 197.0 d 1.03 7.75 necropsy 0.0 0 SD approximated from 95%CI 98091 1998
BDIX/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait female 0 days 52 Kaplan-Meier estimate median 214.0 d 1.42 10.25 necropsy 0.0 0 SD approximated from 95%CI 98092 1998
BDIX.BDIV-D6Mit1-D6Mgh2/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 214 days-254 days 100 Kaplan Meier estimate median 234.0 d 1.0 10.0 necropsy 0.0 0 SD approximated from 95%CI 98130 2018
BDIX.BDIV-D10Mit3-D10Mgh16/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait both 0 days 75 Kaplan-Meier estimate median 247.0 d 3.41 29.5 necropsy 0.0 0 SD approximated from 95%CI 98175 1998
BDIX post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 192 days-236 days 52 Kaplan Meier estimate median 214.0 d 1.53 11.0 necropsy 0.0 0 SD approximated from 95%CI 98126 2018
BDIV post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 0 days 112 Kaplan Meier estimate median 593.0 d necropsy 0.0 0 98141 2018
BDIX/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait female 200 days 109 Kaplan-Meier estimate 49.0 % 0.48 5.0 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98177 1998
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (8 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 32.0 d 0.38 1.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109471 3146
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (4 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 35.0 d 0.76 2.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109472 3146
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (2 mg/kg) (for 49 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 35.0 d 2.65 7.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109477 3146
WM/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 21 33.3 % necropsy 0.0 12 days 111318 3199
BDIX/HanHsd ratio of deaths related to FUDR toxicity to total study population during a period of time DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours) Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2. total life span female 0 days 4 0.0 % necropsy 0.0 26 days India ink stain; tissue stains, tumors white ratio of deaths related to FUDR toxicity to total study population during a period of time (CMO:0003875) 111379 3197
F344/Jcl percentage of study population developing unilateral renal agenesis during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. kidney integrity trait male 900 days 8 0.0 % necropsy 0.0 0 106884 341
BDIX/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 60 2.8 % necropsy 0.0 12 days 111292 3199
BDIX/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 32 0.0 % necropsy 0.0 12 days 111300 3199
WM/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 43 0.0 % necropsy 0.0 12 days 111315 3199
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 76 2.0 % necropsy 0.0 12 days 111234 3199
WM/Nem number of blastocysts implanted per litter trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 12 12.8 null necropsy 0.0 12 days 111262 3199
BDIX/Nem number of blastocysts implanted per litter trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 14 9.4 null necropsy 0.0 12 days 111268 3199
BDIX/HanHsd ratio of deaths related to FUDR toxicity to total study population during a period of time DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours) Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2. total life span female 0 days 5 0.0 % necropsy 0.0 26 days India ink stain; tissue stains, tumors white ratio of deaths related to FUDR toxicity to total study population during a period of time (CMO:0003875) 111380 3197
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. kidney integrity trait male 900 days 12 24.0 % necropsy 0.0 0 106885 341
LOU/MWsl post-treatment survival time from doxorubicin-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then negatively charged liposome-entrapped doxorubicin (2 mg/kg) van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. life span trait male 122 days-170 days 10 median 40.0 d necropsy 0.0 0 post-treatment survival time from doxorubicin-treated IgM immunocytoma (CMO:0003866) 109574 3150
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 50 23.0 % necropsy 0.0 12 days 111256 3199
WM/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 96 0.0 % necropsy 0.0 12 days 111357 3199
WM/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 46 20.8 % necropsy 0.0 12 days 111359 3199
WM/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 96 0.0 % necropsy 0.0 12 days 111364 3199
WM/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 43 0.0 % necropsy 0.0 12 days 111287 3199
WM/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 46 67.6 % necropsy 0.0 12 days 111373 3199
WM/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 29 85.0 % necropsy 0.0 12 days 111374 3199
BDIX/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 45 8.2 % necropsy 0.0 12 days 111375 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 50 19.5 % necropsy 0.0 12 days 111283 3199
BDIX/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 73 9.6 % necropsy 0.0 12 days 111286 3199
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-142 days 13 median 78.5 d 3.63 13.1 necropsy 0.0 14 saline saline control group 111116 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment fluorouracil 5-FU 111125 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment fluorouracil 5-FU 111133 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment interleukin-2 111135 3196
WM/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 28 22.0 % necropsy 0.0 12 days 111317 3199
WM/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 29 13.3 % necropsy 0.0 12 days 111332 3199
WM/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 30 1.4 % necropsy 0.0 12 days 111351 3199
WM/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 29 0.0 % necropsy 0.0 12 days 111353 3199
BDIX/Ifz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait both 0 days 37 58.0 % necropsy 0.0 200 days 111206 3198
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait both 0 days 100 23.8 % necropsy 0.0 200 days 111209 3198
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 1 111031 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group 3 111033 3195
WM/Nem number of blastocysts implanted per litter trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 10 11.4 null necropsy 0.0 12 days 111261 3199
WF.DA-(D19Mit1-D19Mit6)/Kop number of squamous cell tumors of the tongue with diameter greater than 3 mm controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 23 0.78 null 0.14 0.67 necropsy 0.0 0 180 day maximum 70319 1339
DA/Slc non-tongue squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 head and neck integrity trait both 42 days-222 days 47 1.83 null 0.18 1.26 necropsy 0.0 0 until moribund or 180days of exp error not specified 70399 1398
DA/Slc squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 head and neck integrity trait both 42 days-222 days 47 3.34 null 0.23 1.58 necropsy 0.0 0 until moribund or 180days of exp error not specified 70401 1398
BDIX.BDIV-D10Got1-D10Rat45/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait male 0 days 37 Kaplan-Meier estimate median 229.0 d 2.63 16.0 necropsy 0.0 0 SD approximated from 95%CI 98095 1998
SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Stieber D, et al., Int J Cancer. 2007 Jan 17 mammary gland integrity trait female 186 days-191 days 46 7.61 null 0.07 0.45 necropsy 0 DMBA oral gavage 0 necropsy 11342 73
ACI.COP-(D3Mgh16-D3Rat119)/Shul mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 3 0.0 null necropsy 0 11361 75
ACI.COP-(D3Rat130-D3Rat114)/Shul mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 3 0.0 null necropsy 0 11363 75
ACI/SegHsd mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 4 0.0 null necropsy 0 11367 75
SS-Chr 13BN/Mcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 13 5.33 null 1.21 4.38 necropsy 0 DMBA oral gavage 105 days necropsy 11501 86
SS-Chr 16BN/Mcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 13 6.31 null 1.61 5.79 necropsy 0 DMBA oral gavage 105 days necropsy 11504 86
SS.BN-(D6Rat149-D6Got171)/Mcwi ratio of deaths related to DMBA toxicity to total study population during a period of time 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 total life span female 152 days-162 days 15 40.0 % necropsy 0 DMBA oral gavage 105 days ratio of deaths related to DMBA toxicity to total study population during a period of time (CMO:0003809) 65577 86
WF mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days) Shepel LA, et al., Genetics 1998 May;149(1):289-99 mammary gland integrity trait female 181 days-200 days 53 3.62 null 0.27 1.95 necropsy 0.0 DMBA oral gavage 126 days from 126 to 140 days 66100 689
WF.DA-(D19Mit1-D19Mit6)/Kop squamous cell carcinoma of the tongue maximum tumor diameter controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 23 3.17 mm 0.48 2.29 necropsy 0.0 0 180 day maximum 70322 1339
WF squamous cell carcinoma of the tongue maximum tumor diameter controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 50 1.18 mm 0.23 1.64 necropsy 0.0 0 until moribund or 180days of exp error not specified 70398 1398
BDIX/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait both 0 days 109 Kaplan-Meier estimate median 201.0 d 0.6 6.25 necropsy 0.0 0 SD approximated from 95%CI 98174 1998
BDIX.BDIV-D6Mit1-D6Mgh2/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 218 days-340 days 49 Kaplan Meier estimate median 279.0 d 4.36 30.5 necropsy 0.0 0 SD approximated from 95%CI 98129 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 201 days-269 days 47 Kaplan Meier estimate median 235.0 d 2.48 17.0 necropsy 0.0 0 SD approximated from 95%CI 98132 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 227 days-237 days 86 Kaplan Meier estimate median 232.0 d 0.27 2.5 necropsy 0.0 0 SD approximated from 95%CI 98133 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 220 days-237 days 118 Kaplan Meier estimate median 228.0 d 0.39 4.25 necropsy 0.0 0 SD approximated from 95%CI 98138 2018
BDIX.BDIV-D10Got1-D10Rat45/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait both 0 days 77 Kaplan-Meier estimate median 239.0 d necropsy 0.0 0 98176 1998
F344/Jcl percentage of study population developing subcutaneous tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. hypodermis integrity trait male 900 days 8 38.0 % necropsy 0.0 0 CMO:0003387 percentage of study population developing subcutaneous tumors during a period of time 106886 341
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (16 mg/kg) (for 28 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 5 26.0 d 0.89 2.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109470 3146
LOU/M post-treatment survival time from drug-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (4 mg/kg) (for 42 days) de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. life span trait both 154 days-193 days 7 31.0 d 1.51 4.0 necropsy 0.0 0 post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) 109476 3146
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-163 days 18 89.0 % necropsy 0.0 0 two treatment fluorouracil 5-FU 111155 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 82.7 d 3.87 15.0 necropsy 0.0 28 one treatment fluorouracil 5-FU 111117 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-140 days 14 median 77.4 d 6.95 26.0 necropsy 0.0 0 one treatment thymosin alpha-1 111118 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 83.1 d 2.32 9.0 necropsy 0.0 0 one treatment interleukin-2 111119 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-144 days 16 median 80.5 d 3.13 12.5 necropsy 0.0 0 saline control group 111142 3196
BDIX/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 51 6.4 % necropsy 0.0 12 days 111291 3199
WM/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 43 0.0 % necropsy 0.0 12 days 111294 3199
WM/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 16 4.2 % necropsy 0.0 12 days 111295 3199
WM/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 28 6.5 % necropsy 0.0 12 days 111296 3199
WM/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 16 29.1 % necropsy 0.0 12 days 111302 3199
WM/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 21 8.3 % necropsy 0.0 12 days 111304 3199
BDIX/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 51 0.0 % necropsy 0.0 12 days 111312 3199
BDIX/HanHsd ratio of deaths related to FUDR toxicity to total study population during a period of time DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours) Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2. total life span female 0 days 7 14.0 % necropsy 0.0 26 days India ink stain; tissue stains, tumors white ratio of deaths related to FUDR toxicity to total study population during a period of time (CMO:0003875) 111382 3197
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 141 0.0 % necropsy 0.0 12 days 111251 3199
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 10.0 % necropsy 0.0 12 days 111254 3199
BDIX/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111257 3199
BDIX/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 107 1.3 % necropsy 0.0 12 days 111285 3199
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 85 15.9 % necropsy 0.0 12 days 111235 3199
BDIX/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 107 1.3 % necropsy 0.0 12 days 111240 3199
BDIX/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 73 10.5 % necropsy 0.0 12 days 111241 3199
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 74 10.9 % necropsy 0.0 12 days 111255 3199
WM/Nem number of blastocysts implanted per litter trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 12 12.1 null necropsy 0.0 12 days 111264 3199
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 10 33.3 % necropsy 0.0 12 days 111270 3199
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 12 43.4 % necropsy 0.0 12 days 111271 3199
BDIX/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111284 3199
WM/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111336 3199
WM/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 29 15.0 % necropsy 0.0 12 days 111339 3199
BDIX/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 45 0.0 % necropsy 0.0 12 days 111340 3199
BDIX/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 31 3.3 % necropsy 0.0 12 days 111342 3199
WM/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 30 4.2 % necropsy 0.0 12 days 111344 3199
BDIX/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 31 10.8 % necropsy 0.0 12 days 111349 3199
WM/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 46 0.0 % necropsy 0.0 12 days 111352 3199
BDIX/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 31 0.0 % necropsy 0.0 12 days 111356 3199
BDIX/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 45 0.0 % necropsy 0.0 12 days 111361 3199
BDIX/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 31 0.0 % necropsy 0.0 12 days 111363 3199
WAG/OlaHsd metastatic intraperitoneal tumor weight CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. peritoneum integrity trait male 0 days 16 abdominal lesion weight 7.42 g 0.25 1.01 necropsy 0.0 IP injection 21 days CC531 cells 107874 3098
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-162 days 15 median 98.7 d 2.17 8.4 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111123 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 100.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111129 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111130 3196
WM/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 30 0.0 % necropsy 0.0 12 days 111365 3199
BDIV/lfz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait both 0 days 77 0.0 % necropsy 0.0 200 days 111212 3198
BDIV/lfz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait male 0 days 45 0.0 % necropsy 0.0 200 days 111213 3198
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time phosphate buffered saline (0.2 ml) then phosphate buffered saline (0.1 ml) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 3 0.0 % 0.0 0.0 necropsy 0.0 30 days sham surgical group 111027 3195
SS-Chr 6BN/Mcwi ratio of deaths related to DMBA toxicity to total study population during a period of time 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 total life span female 152 days-162 days 20 95.0 % necropsy 0 DMBA oral gavage 105 days ratio of deaths related to DMBA toxicity to total study population during a period of time (CMO:0003809) 65578 86
SS-Chr 19BN/Mcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 14 8.79 null 1.25 4.68 necropsy 0 DMBA oral gavage 105 days necropsy 11507 86
ACI.COP-(D3Mgh16-D3Rat119)/Shul mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 8 4.3 null 1.13 3.2 necropsy 0 11362 75
BN/SsNHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait male 0 days 43 0.0 % necropsy 0.0 0 69375 1157
DA/Slc squamous cell carcinoma of the tongue maximum tumor diameter controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 10.35 mm 0.95 4.26 necropsy 0.0 0 180 day maximum 70323 1339
WF.DA-(D19Mit1-D19Mit6)/Kop squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. head and neck integrity trait both 42 days-222 days 23 4.75 null 0.36 1.75 necropsy 0.0 0 180 day maximum 70325 1339
F344/NRrrc percentage of study population developing liver tumors during a period of time controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) Yan Y, et al., Carcinogenesis 2002 Jan;23(1):189-96. liver integrity trait not specified 175 days 11 100.0 % necropsy 0.0 0 liver tumor incidence 68164 890
BDIX.BDIV-D10Mit3-D10Mgh16/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait male 0 days 38 Kaplan-Meier estimate median 241.0 d 1.22 7.5 necropsy 0.0 0 SD approximated from 95%CI 98093 1998
BDIX.BDIV-D10Mit3-D10Mgh16/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait male 200 days 38 Kaplan-Meier estimate 13.9 % 0.73 4.5 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98099 1998
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160 days-260 days 20 5.6 null necropsy 0.0 0 tumor size reach 1-1.5 cm 11377 76
WKY/NHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Lan H, et al., Genetics 2001 Jan;157(1):331-9 mammary gland integrity trait female 169 days-174 days 17 0.0 null necropsy 0 3X3 mm diameter or larger 11741 141
WF/NHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Lan H, et al., Genetics 2001 Jan;157(1):331-9 mammary gland integrity trait female 169 days-174 days 21 7.3 null 0.98 4.5 necropsy 0 3X3 mm diameter or larger 11742 141
COP/OlaHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 mammary gland integrity trait female 155 days-160 days 16 0.25 null 0.1 0.4 necropsy 0 3X3 mm diameter or larger 11747 143
SS.BN-(D6Rat149-D6Rat18)/Mcwi ratio of deaths related to DMBA toxicity to total study population during a period of time 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 total life span female 152 days-162 days 15 80.0 % necropsy 0 DMBA oral gavage 105 days ratio of deaths related to DMBA toxicity to total study population during a period of time (CMO:0003809) 65576 86
WF/Kga squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. head and neck integrity trait both 42 days-222 days 20 2.75 null 0.28 1.25 necropsy 0.0 0 180 day maximum 70324 1339
WF/Kga number of squamous cell tumors of the tongue with diameter greater than 3 mm controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 0.35 null 0.11 0.49 necropsy 0.0 0 180 day maximum 70318 1339
WF non-tongue squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 head and neck integrity trait both 42 days-222 days 50 0.78 null 0.17 1.17 necropsy 0.0 0 until moribund or 180days of exp error not specified 70400 1398
WF number of squamous cell tumors of the tongue with diameter greater than 5 mm controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 50 0.04 null 0.03 0.2 necropsy 0.0 0 until moribund or 180days of exp error not specified 70394 1398
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait male 0 days 87 5.7 % necropsy 0.0 0 69374 1157
F344/NHsd percentage of study population developing hepatocellular carcinoma during a period of time N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7. liver integrity trait not specified 0 days 9 89.0 % necropsy 0.0 N-nitrosodiethylamine 490 days CMO:0001068 96757 912
ACI/NJcl percentage of study population developing stomach tumors during a period of time controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) Ushijima T, et al., Cancer Res 2000 Feb 15;60(4):1092-6. stomach integrity trait not specified 56 days-560 days 21 76.0 % necropsy 0.0 0 84753 1478
BDIX.BDIV-D6Mit1-D6Mgh2/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 190 days-258 days 51 Kaplan Meier estimate median 224.0 d 2.38 17.0 necropsy 0.0 0 SD approximated from 95%CI 98128 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 209 days-235 days 56 Kaplan Meier estimate median 222.0 d 0.57 4.25 necropsy 0.0 0 SD approximated from 95%CI 98136 2018
BDIX/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 60 6.8 % necropsy 0.0 12 days 111320 3199
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-163 days 18 median 99.7 d 4.38 18.6 necropsy 0.0 0 two treatment fluorouracil 5-FU 111143 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-164 days 18 median 101.3 d 3.87 16.4 necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111144 3196
BDIX/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 32 19.2 % necropsy 0.0 12 days 111293 3199
WM/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 43 0.0 % necropsy 0.0 12 days 111301 3199
WM/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 28 18.0 % necropsy 0.0 12 days 111303 3199
BDIX/Nem number of fetuses with cardiovascular malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 51 2.6 % necropsy 0.0 12 days 111305 3199
BDIX/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 60 2.8 % necropsy 0.0 12 days 111313 3199
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-144 days 16 100.0 % necropsy 0.0 0 two treatment regimen saline control group 111154 3196
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 15.8 % necropsy 0.0 12 days 111245 3199
BDIX/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 73 0.0 % necropsy 0.0 12 days 111250 3199
BDIX/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 107 0.0 % necropsy 0.0 12 days 111258 3199
BDIX/Nem number of blastocysts/embryos lost postimplantation to litter size ratio control condition Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 13 21.6 % necropsy 0.0 12 days 111275 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 76 2.0 % necropsy 0.0 12 days 111279 3199
BDIX/OrlIco post-insult time of death due to metastatic liver tumors PRObR1 cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days) Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. life span trait male 174 days-230 days 6 median 114.0 d necropsy 0.0 0 post-insult time of death due to metastatic liver tumors (CMO:0003882) survival 107418 3085
WM/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 28.7 % necropsy 0.0 12 days 111236 3199
BDIX/Nem number of fetuses with external malformations to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111239 3199
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (30 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 85 8.6 % necropsy 0.0 12 days 111244 3199
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 74 13.9 % necropsy 0.0 12 days 111246 3199
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 50 27.0 % necropsy 0.0 12 days 111247 3199
LOU/MWsl post-treatment survival time from doxorubicin-treated IgM immunocytoma rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then doxorubicin (2 mg/kg) van Hoesel QG, etal., Cancer Res. 1984 Sep;44(9):3698-705. life span trait male 116 days-138 days 10 median 23.0 d necropsy 0.0 0 post-treatment survival time from doxorubicin-treated IgM immunocytoma (CMO:0003866) 109573 3150
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 87.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111137 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111138 3196
SD-Cftrem1Apb percentage of study population developing meconium ileus during a period of time control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. intestine integrity trait not specified 7 days 0 16.0 % 0.0 necropsy 0.0 0 percentage of study population developing meconium ileus during a period of time (CMO:0003881) 111463 3184
WM/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 46 0.0 % necropsy 0.0 12 days 111366 3199
BDIX/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 45 44.6 % necropsy 0.0 12 days 111368 3199
BDIX/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 31 28.3 % necropsy 0.0 12 days 111370 3199
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % necropsy 0.0 0 saline control group 111132 3196
BDIX/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 0.0 % necropsy 0.0 12 days 111327 3199
BDIX/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 45 0.0 % necropsy 0.0 12 days 111347 3199
WM/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 96 0.0 % necropsy 0.0 12 days 111350 3199
BDIX/Nem number of blastocysts implanted per litter control condition Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 13 9.2 null necropsy 0.0 12 days 111266 3199
BDIX/Nem number of blastocysts/embryos lost postimplantation to litter size ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 14 44.9 % necropsy 0.0 12 days 111277 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 0.0 % necropsy 0.0 12 days 111281 3199
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group A 111028 3195
ACI.COP-(D6Rat80-D6Rat146)/Shul mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 3 0.0 null necropsy 0 11359 75
WF/Kga squamous cell carcinoma of the tongue maximum tumor diameter controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 1.15 mm 0.17 0.75 necropsy 0.0 0 180 day maximum 70321 1339
DA/Slc squamous cell carcinoma of the tongue tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. tongue integrity trait both 42 days-222 days 20 2.35 null 0.22 0.99 necropsy 0.0 0 180 day maximum 70317 1339
BDIX.BDIV-D10Got1-D10Rat45/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait male 200 days 37 Kaplan-Meier estimate 32.7 % 1.4 8.5 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98101 1998
BDIV/lfz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait female 0 days 32 0.0 % necropsy 0.0 200 days 111214 3198
SS.BN-(D6Rat149-D6Arb3)/Mcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 14 4.77 null 0.64 2.39 necropsy 0 DMBA oral gavage 105 days necropsy 65571 86
ACI.COP-(D6Rat80-D6Rat146)/Shul mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 17 2.4 null 0.41 1.7 necropsy 0 11360 75
ACI.COP-(D3Rat130-D3Rat114)/Shul mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 17 4.5 null 0.73 3.0 necropsy 0 11364 75
ACI.COP-(D10Mgh8-D10Rat4)/Shul mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 12 4.8 null 1.04 3.6 necropsy 0 11366 75
SS/JrHsdMcwi mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 mammary gland integrity trait female 152 days-162 days 40 2.45 null 0.21 1.32 necropsy 0 DMBA oral gavage 105 days necropsy 11488 86
SS.BN-(D6Rat149-D6Arb3)/Mcwi ratio of deaths related to DMBA toxicity to total study population during a period of time 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 total life span female 152 days-162 days 14 57.0 % necropsy 0 DMBA oral gavage 105 days ratio of deaths related to DMBA toxicity to total study population during a period of time (CMO:0003809) 65575 86
DA/Slc number of squamous cell tumors of the tongue with diameter greater than 5 mm controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 47 1.17 null 0.09 0.64 necropsy 0.0 0 until moribund or 180days of exp error not specified 70393 1398
DA/Slc squamous cell carcinoma of the head and neck tumor number controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. head and neck integrity trait both 42 days-222 days 20 5.55 null 0.4 1.79 necropsy 0.0 0 180 day maximum 70326 1339
DRH/Seac percentage of study population developing liver tumors during a period of time controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) Yan Y, et al., Carcinogenesis 2002 Jan;23(1):189-96. liver integrity trait not specified 175 days 5 0.0 % necropsy 0.0 0 liver tumor incidence 68165 890
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait female 0 days 96 13.5 % necropsy 0.0 0 69372 1157
DA.PVG.1AV1-(D4Got126-D4Got136) ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 21 24.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68131 838
BN/SsNHsd percentage of study population developing hepatocellular carcinoma during a period of time N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7. liver integrity trait not specified 0 days 10 10.0 % necropsy 0.0 N-nitrosodiethylamine 490 days CMO:0001068 96758 912
BUF/NacJcl percentage of study population developing stomach tumors during a period of time controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) Ushijima T, et al., Cancer Res 2000 Feb 15;60(4):1092-6. stomach integrity trait not specified 56 days-560 days 22 14.0 % necropsy 0.0 0 84752 1478
BDIX.BDIV-D10Mit3-D10Mgh16/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait female 0 days 37 Kaplan-Meier estimate median 272.0 d necropsy 0.0 0 SD approximated from 95%CI 98094 1998
BDIX.BDIV-D10Got1-D10Rat45/Zte post-insult time of death N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. life span trait female 0 days 40 Kaplan-Meier estimate median 348.0 d necropsy 0.0 0 98096 1998
BDIX/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, et al., G3 (Bethesda). 2015 Nov 3;6(1):59-65. doi: 10.1534/g3.115.021170. trigeminal nerve integrity trait male 200 days 57 Kaplan-Meier estimate 55.0 % 0.6 4.5 necropsy 0.0 ENU injection 200 days kaplan meier estimate SD approximated from 95%CI 98097 1998
BDIX.BDIV-D6Rat132-D6Mgh3/Zte post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 212 days-250 days 39 Kaplan Meier estimate median 231.0 d 1.52 9.5 necropsy 0.0 0 SD approximated from 95%CI 98131 2018
SS.ZUC-Leprfa-/-/Slc ratio of survivors of metabolic syndrome to total study population during a period of time control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total life span male 126 days 20 35.0 % necropsy 0.0 0 ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) 101910 2642
ACI/SegHsd percentage of study population developing subcutaneous tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. hypodermis integrity trait male 900 days 12 0.0 % necropsy 0.0 0 CMO:0003387 percentage of study population developing subcutaneous tumors during a period of time 106887 341
BDIX/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 51 1.5 % necropsy 0.0 12 days 111319 3199
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-157 days 15 median 94.0 d 2.63 10.2 necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111120 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-145 days 15 median 81.7 d 3.87 15.0 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111121 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-186 days 21 median 122.6 d 2.42 11.1 necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111145 3196
WM/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 16 33.3 % necropsy 0.0 12 days 111288 3199
WM/Nem number of fetuses with visceral malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 21 31.5 % necropsy 0.0 12 days 111290 3199
BDIX/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 51 0.0 % necropsy 0.0 12 days 111298 3199
BDIX/Nem number of fetuses with hydrocephaly to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 60 0.0 % necropsy 0.0 12 days 111299 3199
WM/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 16 0.0 % necropsy 0.0 12 days 111309 3199
WM/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 21 8.3 % necropsy 0.0 12 days 111311 3199
BDIX/Nem number of fetuses with renal malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 32 5.9 % necropsy 0.0 12 days 111314 3199
WM/Nem number of fetuses with left umbilical artery to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 16 33.3 % necropsy 0.0 12 days 111316 3199
WM/Nem number of blastocysts implanted per litter control condition Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 13 12.6 null necropsy 0.0 12 days 111260 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 141 0.0 % necropsy 0.0 12 days 111278 3199
BDIX/OrlIco post-insult time of death due to metastatic liver tumors PROb cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days) Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. life span trait male 94 days-130 days 6 median 34.0 d necropsy 0.0 0 post-insult time of death due to metastatic liver tumors (CMO:0003882) survival 107419 3085
BDIX/OrlIco post-insult time of death due to metastatic liver tumors PROb cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) Cordel S, etal., Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6. life span trait male 126 days-190 days 6 median 66.0 d necropsy 0.0 0 post-insult time of death due to metastatic liver tumors (CMO:0003882) survival 107420 3085
WM/Nem number of blastocysts/embryos lost postimplantation to litter size ratio control condition Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 13 13.0 % necropsy 0.0 12 days 111269 3199
BDIX/HanHsd ratio of deaths related to FUDR toxicity to total study population during a period of time DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours) Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2. total life span female 0 days 7 14.0 % necropsy 0.0 26 days India ink stain; tissue stains, tumors white ratio of deaths related to FUDR toxicity to total study population during a period of time (CMO:0003875) 111381 3197
BDIX/Ifz percentage of study population developing trigeminal nerve neurilemmomas during a period of time N-ethyl-N-nitrosourea (80 ug/g) Koelsch B, etal., Physiol Genomics. 2011 May 1;43(10):631-9. doi: 10.1152/physiolgenomics.00246.2010. Epub 2011 Mar 22. peripheral nervous system integrity trait female 0 days 20 43.9 % necropsy 0.0 200 days 111208 3198
BDIX/HanHsd ratio of deaths related to FUDR toxicity to total study population during a period of time DHD/K12/TRb - Sp-5 cells (1 X 10E6) then floxuridine (1 mg/kg/d) (for 7 days) Ng B, etal., Ann Thorac Surg. 1995 Jan;59(1):205-8. doi: 10.1016/0003-4975(94)00774-2. total life span female 0 days 5 20.0 % necropsy 0.0 26 days India ink stain; tissue stains, tumors white ratio of deaths related to FUDR toxicity to total study population during a period of time (CMO:0003875) 111378 3197
WM/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 76 0.0 % necropsy 0.0 12 days 111243 3199
BDIX/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 96 0.0 % necropsy 0.0 12 days 111248 3199
BDIX/Nem number of fetuses with exencephaly to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 107 0.0 % necropsy 0.0 12 days 111249 3199
WM/Nem number of fetuses with brain hernia to total number of live fetuses ratio trypan blue (20 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 76 2.0 % necropsy 0.0 12 days 111252 3199
WM/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 29 24.1 % necropsy 0.0 12 days 111325 3199
BDIX/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 45 0.0 % necropsy 0.0 12 days 111326 3199
BDIX/Nem number of fetuses with skeletal malformations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 31 6.7 % necropsy 0.0 12 days 111328 3199
BDIX/Nem number of fetuses with cranial malformations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 45 0.0 % necropsy 0.0 12 days 111333 3199
WM/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 46 16.3 % necropsy 0.0 12 days 111338 3199
BDIX/Nem number of fetuses with vertebral malformations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 47 0.0 % necropsy 0.0 12 days 111341 3199
WM/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 29 0.0 % necropsy 0.0 12 days 111346 3199
BDIX/Nem number of fetuses with sternum variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 47 1.7 % necropsy 0.0 12 days 111348 3199
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111136 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111139 3196
WAG/OlaHsd metastatic intraperitoneal tumor weight CC531 cells (5 X 10E6) (for 21 days) then phosphoramidon (250 mg) (for 21 days) Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2. peritoneum integrity trait male 0 days 16 abdominal lesion weight 3.22 g 0.27 1.06 necropsy 0.0 IP injection 21 days CC531 cells 107875 3098
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment interleukin-2 111127 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111128 3196
BDIX/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (0 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 45 0.0 % necropsy 0.0 12 days 111354 3199
BDIX/Nem number of fetuses with cervical rib variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 47 0.0 % necropsy 0.0 12 days 111355 3199
WM/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (40 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 30 12.5 % necropsy 0.0 12 days 111358 3199
WM/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 29 41.7 % necropsy 0.0 12 days 111360 3199
BDIX/Nem number of fetuses with lumbar rib variations to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 47 0.0 % necropsy 0.0 12 days 111362 3199
BDIX/Nem number of blastocysts implanted per litter trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. embryo implantation trait both -1 days 16 10.5 null necropsy 0.0 12 days 111267 3199
WM/Nem number of fetuses with eye malformations to total number of live fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetus integrity trait both -1 days 74 26.1 % necropsy 0.0 12 days 111282 3199
BDIX/Nem number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 47 22.2 % necropsy 0.0 12 days 111369 3199
BDIX/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (60 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 47 14.1 % necropsy 0.0 12 days 111376 3199
BDIX/Nem number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio trypan blue (120 mg/kg) Hoshino K, etal., Teratology. 1988 Jan;37(1):43-50. doi: 10.1002/tera.1420370108. fetal growth trait both -1 days 31 51.7 % necropsy 0.0 12 days 111377 3199
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group B 111029 3195
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259 days 21 7.0 null 1.16 5.3 necropsy 0 11368 75
DA.PVG.1AV1-(D4Got126-D4Got136) ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 19 0.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68127 838
DA/Slc squamous cell carcinoma of the tongue tumor number controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 47 1.49 null 0.1 0.66 necropsy 0.0 0 until moribund or 180days of exp error type not specified 70395 1398
DA/Slc squamous cell carcinoma of the tongue maximum tumor diameter controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) Tanuma J, et al., Cancer Res 1998 Apr 15;58(8):1660-4 tongue integrity trait both 42 days-222 days 47 12.77 mm 0.65 4.49 necropsy 0.0 0 until moribund or 180days of exp error not specified 70397 1398
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment thymosin alpha-1 111126 3196